Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B

Background and Aim In areas of the world where tenofovir disoproxil fumarate is not marketed, adefovir (ADV) + lamivudine (LAM) is recommended and widely used for LAM‐resistant chronic hepatitis B (CHB). This study hypothesizes that entecavir (ETV) + ADV, where both components are active against LAM...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2014-07, Vol.29 (7), p.1485-1493
Main Authors: Heo, Jeong, Ahn, Sang Hoon, Kweon, Young-Oh, Kim, Byung-Ho, Chan, Henry L Y, Horban, Andrzej, Wongcharatrawee, Suchat, Llamoso, Cyril, Lee, Kwan Sik
Format: Article
Language:English
Subjects:
Adenine - administration & dosage
Adenine - analogs & derivatives
Adolescent
Adult
Aged
Antiviral Agents - administration & dosage
antiviral resistance
combination rescue therapy
Drug Resistance, Viral
Drug Therapy, Combination
Female
Hepatitis B e Antigens - immunology
Hepatitis B e Antigens - metabolism
Hepatitis B virus
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - immunology
Hepatitis B, Chronic - virology
Humans
Lamivudine - administration & dosage
lamivudine-refractory
Male
Middle Aged
nucleos(t)ide analog
Organophosphonates - administration & dosage
Time Factors
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim In areas of the world where tenofovir disoproxil fumarate is not marketed, adefovir (ADV) + lamivudine (LAM) is recommended and widely used for LAM‐resistant chronic hepatitis B (CHB). This study hypothesizes that entecavir (ETV) + ADV, where both components are active against LAM‐resistant hepatitis B virus (HBV), will provide greater antiviral potency than ADV + LAM where only ADV is active. Methods Open‐label, randomized trial in hepatitis B virus e antigen‐positive LAM‐experienced CHB patients with LAM resistance treated with ETV 1 mg + ADV 10 mg (n = 138), ADV + LAM 100 mg (n = 137), or ETV (n = 140). Results At week 48, there was no significant difference in the primary endpoint of HBV‐DNA 
ISSN:0815-9319
1440-1746
DOI:10.1111/jgh.12567